Introduction
============

Several trials have demonstrated that antibiotics are beneficial over placebo for the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD) ([@b2-copd-3-319]; [@b16-copd-3-319]; [@b14-copd-3-319]). COPD guidelines recommend the use of antibiotics when clinical signs of infection are apparent; for example, increased sputum volume and purulence, and/or fever ([@b10-copd-3-319]). Antimicrobial choices can be based upon the local patterns of antibiotic sensitivity among the most common responsible pathogens ([@b10-copd-3-319]). Canadian guidelines recommend the use of amoxicillin, doxycycline, trimethoprim/sulfamethoxazole, second or third-generation cephalosporins, or extended spectrum macrolides in the absence of risk factors, whereas fluoroquinolones or beta-lactam/beta-lactamase inhibitor (amoxicillin/clavulanic acid) are suggested for patients who have an forced expiratory volume in one second (FEV~1~) lower than 50% of the predicted, four or more COPD exacerbations per year, ischemic heart disease, home oxygen use, chronic use of oral corticosteroids, and/or antibiotherapy taken in the previous three months ([@b13-copd-3-319]). The authors do however, specify that this is a level 3c recommendation ("consensus from expert groups based on clinical experience and poor evidence to support a recommendation for or against use"). Furthermore, it is also specified that antibiotics for patients with no risk factors when combined with prednisone may suffice ([@b13-copd-3-319]).

Most patients included in our COPD home management program have the risk factors associated with the use of second line antimicrobial agents (ie, for patients with risk factors), specified in the Canadian COPD guidelines, but various antibiotics, including first-line agents, are used. Therefore, we sought to describe the type of antibiotics that are used by COPD patients included in our home management program and to estimate the failure rate associated with this therapy.

Methods
=======

We conducted a retrospective cohort study to describe the different antibiotics that are used for COPD patients included in our home management program, and estimate the treatment failure rates. All patients participating in the COPD home-management program of l'Hôpital du Sacré-Coeur de Montréal (HSCM) were included in the analysis if they had follow-up data for at least 12 months. This program follows patients for whom COPD represents a chronic disease that has an important impact on their quality of life and who are at risk of severe exacerbations; for example, have had previous exacerbations requiring acute care. Patient charts updated at least every month by doctors, nurses, and pharmacists were used for data collection. Cohort entry corresponded to inclusion in the program (started in 1995) and follow-up until exclusion from the program, death, or November 31st, 2004, whichever occurred first. Antibiotics were initiated at home for these patients when they reported at least two of the following criteria: dyspnea, increased sputum production, increased sputum volume ([@b2-copd-3-319]). The selection of an appropriate antibiotic for the patient's action plan is at the physician's discretion and is not based upon prespecified criteria with the exception of drug allergy or intolerance. Usually, the action plan (antibiotic) is prescribed for a year and rotation from one antibiotic to another over the course of the year to treat subsequent exacerbations is not done unless treatment fails. Microbiologic data is not usually available to select the antibiotic; patients who begin an exacerbation are managed by telephone communication between the nurse and the patient. Usual treatment duration is of 10 days (with the exception of azithromycin which in most cases is prescribed for 5 days). An intravenous antibiotic regimen and a concomitant use of two antibiotics were excluded from the analysis, since these cases are managed differently (usual protocol is not followed for these cases at our program). Patients included in this program are followed by one of the respiratory physicians at HSCM with meetings once or twice a year at the outpatient clinic.

Data collected included antibiotic treatments (number and agents used), number of emergency room visits for a COPD exacerbation, number of hospitalizations for a COPD exacerbation, use of oral and inhaled corticosteroids, use of bronchodilators (inhaled short and long-acting bronchodilators, theophylline), FEV~1~, level of dyspnea (based on the cardiac rhythm management dyspnea index; scale 1--5, a higher score implies a higher level of dyspnea), co-morbidities, age, sex, smoking status, home oxygen use, hypercapnia, and level of autonomy (scale 1--6, a higher score implies a better level of autonomy).

The main outcome was the type of antimicrobial agents prescribed to the patients in the cohort. The secondary outcome was treatment failure in the 30 days following the initiation of the antibiotic. Treatment failure was considered if one of the following events occurred in the 30-day period following the initiation of the antibiotic: prescription of the same antibiotic for home management once the initial treatment has been completed; use of a different antimicrobial agent for home management of a COPD exacerbation (change in the antibiotic initially prescribed before treatment completion or upon treatment completion); emergency room visit for a COPD exacerbation (as soon as 1 day following treatment initiation); and hospitalization for a COPD exacerbation (as soon as 1 day following treatment initiation). These were described separately and then, treatment failure was assessed based on the occurrence of one of these four events; if more than one occurred in the 30-day period, only one treatment failure was calculated. Furthermore, a delay of at least 30 days between two exacerbations in the same patient was mandatory to consider the occurrence of a new COPD exacerbation requiring antibiotic therapy. The conduct of this project was approved by the ethics committee of our institution.

Statistical analysis
--------------------

Descriptive statistics -- proportions and standard deviation -- were calculated to describe the type of antibiotics prescribed.

Results
=======

The initial cohort included 2288 episodes of oral antibiotic treatments received by 152 COPD patients included in the home management program between 1995 and 2004. We excluded 972 antibiotic treatments that were preceded in the 30 days by a COPD exacerbation (hospitalization, emergency room visit, another antibiotic therapy), and 136 episodes for which complete clinical data of the patients were not available. Therefore, a total of 1180 episodes of antibiotic treatment received by 152 patients were analyzed. The distribution of the characteristics of the patients at cohort entry and antibiotic choices are found in [Table 1](#t1-copd-3-319){ref-type="table"} and [Table 2](#t2-copd-3-319){ref-type="table"}. All patients included in our cohort had an FEV~1~ lower than 50% at cohort entry, and therefore were in the category "with risk factors" based on the Canadian guidelines. The most frequently used antibiotics were cefuroxime (45.9%) and ciprofloxacin (21.1%). A total 473 of the 1180 antibiotic treatments (40.0%) were combined with prednisone.

Overall, 348 of the 1180 episodes led to a treatment failure (29.5%), including 103 hospitalizations for a COPD exacerbation, 29 emergency room visits, 44 repeated treatments with the same antibiotic, and 172 repeated treatments with a different antibiotic ([Table 3](#t3-copd-3-319){ref-type="table"}). The average time between the initiation of the antibiotic and the treatment failure was 15.3 days (median of 14 days).

A total of 418 of the 1180 treatments prescribed (35.4%) were antibiotics recommended for patients with risk factors according to the Canadian COPD guidelines (ie, amoxicillin/clavulanic acid or fluroquinolones). The failure rates associated with the use of an antibiotic for patients with risk factors was of 32.8% while it was of 27.7% for antibiotics in the category of patients without risk factors. The risk of having a treatment failure was slightly higher when an antibiotic for patients with risk factors was prescribed (data not shown, available upon request).

Discussion
==========

Overall, our failure rate was greater than the ones reported in the literature that vary from 12% to 21% ([@b1-copd-3-319]; [@b6-copd-3-319]; [@b12-copd-3-319]). Potential explanations for this difference are our study's inclusion of patients with a more severe form of the disease, and the use of a different definition of failure ([@b1-copd-3-319]; [@b6-copd-3-319]; [@b12-copd-3-319]). Furthermore, about 65% of patients received an antibiotic for patients with no risk factors, while they were considered at risk based on their characteristics (such as FEV~1~). A deficiency in guideline conformity and under use with regard to COPD treatment has been previously reported ([@b11-copd-3-319]; [@b15-copd-3-319]; [@b5-copd-3-319]; [@b4-copd-3-319]; [@b7-copd-3-319]; [@b3-copd-3-319]; [@b8-copd-3-319], [@b9-copd-3-319]). However, antibiotic treatment recommendations in the Canadian COPD guidelines are not based on a high level of evidence.

The main strength of our study is that we collected data from a real clinical setting. But our results cannot be generalized to all COPD patients since the patients included in our program have a severe form of the disease. We attempted to compare failure rates between different classes of antibiotic (data not shown) by performing a Chi-square test and a Poisson regression analysis, but our study design had many limitations such as lack of power and the absence of randomization. In fact, patients who received large spectrum antibiotics had a higher risk of failure even after adjusting our results for confounding variables. This suggests that patients who received large spectrum of antibiotics were the ones with the most severe disease (ie, higher risk of failure) and we could not completely exclude the possibility of residual confounding of disease severity in the analysis of our results.

In conclusion, a wide range of antibiotics are prescribed to our patients with moderate to severe COPD to treat mild exacerbations at home. Overall, the initiation at home of an antibiotic for an acute exacerbation of COPD failed to prevent the use of another antibiotic treatment, an emergency room visit, or a hospitalization in 30% of the cases. Results of this study should alert the clinician to the high risk of treatment failure when managing mild exacerbations of COPD at home in patients with severe disease. Furthermore, our results support the implementation of strategies to better promote the application of clinical practice guidelines for the management of chronic diseases.
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###### 

Characteristics of the patients at their entry in the COPD home management program

  Characteristics (n = 152)                                          N (%)
  ------------------------------------------------------------------ ------------------------
  Gender: Male                                                       76 (50.0)
  Mean age:                                                          
  49--64 years old                                                   31 (20.4)
  65--74 years old                                                   60 (39.5)
  ≥75 years old                                                      61 (40.1)
  BMI:                                                               
  320                                                                37 (24.3)
  20--29                                                             92 (60.5)
  ≥30                                                                23 (15.1)
  Smoking status:                                                    
  Past history of smoking                                            120 (79.0)
  Smoker                                                             26 (17.1)
  No history of smoking                                              6 (4.0)
  Number of co-morbiditites:                                         
  32                                                                 88 (57.9)
  ≥2                                                                 64 (42.1)
  Dyspnea index (scale of 1--5)                                      
  1--2                                                               19 (12.5)
  3                                                                  29 (19.1)
  4--5                                                               104 (68.4)
  Level of autonomy (scale 1--6)                                     
  1--3                                                               78 (55.3)
  4--6                                                               63 (44.7)
  Home oxygen                                                        70 (46.4)
  Use of a short-acting bronchodilator (albuterol and ipratropium)   152 (100)
  Use of a long-acting beta-2 agonist                                87 (57.2)
  Use of an inhaled corticosteroid                                   132 (86.8)
  Use of theophylline                                                56 (36.8)
  Continuous use of oral corticosteroids                             22 (14.6)
  FEV~1~                                                             Mean (± SD)
                                                                     32.3% predicted (±9.1)
  Annual rate of exacerbations                                       2.9 (±2.3)

**Notes:** The mean number of pack-years of smoking was unknown; Based on the CRM dyspnea index: a higher score implies a higher level of dyspnea; Questionnaire developed for our program (not validated): a higher score implies a better level of autonomy. The six-minute walk distance is unknown.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in one second; SD, standard deviation.

###### 

Antibiotics used to treat acute exacerbations of COPD at home

  Antibiotics used (n = 1180 treatments)                                                                                                                        N (%)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Cefuroxime                                                                                                                                                    542 (45.9)
  Ciprofloxacin                                                                                                                                                 249 (21.1)
  Levofloxacin                                                                                                                                                  73 (6.2)
  Azithromycin                                                                                                                                                  56 (4.8)
  Amoxicillin                                                                                                                                                   49 (4.2)
  Moxifloxacin                                                                                                                                                  48 (4.1)
  Trimethoprim-sulfamethoxazole                                                                                                                                 41 (3.5)
  Gatifloxacin                                                                                                                                                  24 (2.0)
  Amoxicillin-clavulanic acid                                                                                                                                   20 (1.7)
  Others (ampicillin, cephalexin, cefaclor, cefixime, cefprozil, clindamycin, cloxacillin, erythromycin, ofloxacin, penicillin, pivampicillin, trovafloxacin)   37 (3.1)

###### 

Description of treatment failure (N = 348 failures for 1180 episodes of treatment)

  Type of failure                                                        N (%)
  ---------------------------------------------------------------------- ------------
  Emergency room visit                                                   29 (8.3)
  Hospitalization                                                        100 (28.7)
  Re-prescription of the same antibiotic                                 44 (12.6)
  Re-prescription of the same antibiotic followed by a hospitalization   1 (0.3)
  Prescription of a different antibiotic                                 172 (49.4)
  Prescription of a different antibiotic followed by a hospitalization   2 (0.6)
